Since the publication of the previous edition of Tumors of the Esophagus and Stomach, great advances in many areas of tumor biology have led to a better understanding of the pathogenesis, pathology, and molecular biology of epithelial and stromal malignancies of the upper gastrointestinal tract. Many of these advances have led to specific improvements in diagnosis, prognosis, treatment, and thus, survival in patients affected by these tumors. This edition of the Fascicle was written to highlight these advances, and more specifically, to help pathologists diagnose diseases more accurately and understand how pathology contributes to clinical treatment in the new age of personalized and targeted therapy.
Notable advances described in this publication include:
• expansion of our understanding of the pathologic features and molecular pathogenesis of carcinomas of the esophagus and stomach, most of which develop through a chronic inflammation-metaplasia-dysplasia-carcinoma sequence. Important refinements in the classification of neoplastic precursor lesions have been made since the last AFIP series, including the morphologic and endoscopic subtypes, and this has led to improvements in surgical treatment with a strong trend toward minimization in the form of endoscopic mucosal and submucosal dissections
• discovery of new diseases, such as gastric adenocarcinoma and proximal polyposis syndrome (GAPPS), a special variant of familial adenomatous polyposis, and significant advances in our knowledge regarding the molecular characterization of genetic polyposis syndromes
• great expansion in the molecular-pathology correlation, morphologic diversity, classification, and therapeutic options of gastrointestinal stromal tumors (GISTs)
• reclassification and refinement of prognostic factors related to neuroendocrine tumors
• improvements in the role of cytology in the diagnosis of tumors of the upper gastrointestinal tract.
This book has been written with the pathologist in mind first by using tables that illustrate salient pathologic, molecular, and differential diagnostic features of key entities that are often difficult to distinguish from each other. Specific color photographs of classic tumors and morphologic variants often difficult to recognize are used throughout.
• Robert D. Odze, MD, FRCP, Professor of Pathology; Chief, GI Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
• Elizabeth A. Montgomery, MD, Director, Gastrointestinal and Liver Pathology, Professor of Pathology, Oncology, and Orthopedic Surgery, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.
• Helen H. Wang, MD, Professor of Pathology, Medical Director, Cytology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
• Gregory Y. Lauwers, MD, Senior Pathologist, Department of Oncologic Sciences, Department of Pathology and Cell Biology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA.
• Joel K. Greenson, MD, Professor, Gastrointestinal and Hepatobiliary Pathology, University of Michigan Medical School, Ann Arbor, Michigan, USA.
• Fátima Carneiro, MD, PhD, Faculty of Medicine of the University of Porto, Centro Hospitalar de São João, Institute of Molecular Pathology and Immunology at the University of Porto, Institute for Research Innovation in Health, Porto, Portugal.
• Jason L. Hornick, MD, PhD, Director, Surgical Pathology and Immunohistochemistry, Associate Professor of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.